Poster List

Posters listed alphabetically by Presenting Author Surname

Please note, all content, speakers and board numbers are subject to change

Board Number	Poster	Theme
1	**Transforming the Breast Cancer Now Biobank Data into the OMOP Common Data Model** **Maryam Abdollahyan**[1], Claude Chelala[1] [1]Centre for Cancer Biomarkers & Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK	Other
2	**Mammography AI Breast Cancer Risk Stratification in a UK Population** **Daniel Adams**[1,2], Reuben Frost[1,2], Penny Coulson[1], Amy Berrington[1,2], Elizaveta Semenova[3], Michael Jones[1,2], Montserrat Garcia-Closas[1,2] [1]Division of Genetics and Epidemiology, The Institute Of Cancer Research, London, UK, [2]Cancer Epidemiology and Prevention Research Unit, The Institute of Cancer Research and Imperial College London, London, UK, [3]School of Public Health, Imperial College London, London, UK	Genetics/Screening/Early detection
3	**Invasive lobular carcinoma in the breast and its association with residual cancer in re-excisions and locoregional recurrence (ISRCTN12077301)** **Anna Allfelt**[1], Pär-Ola Bendahl[1], Kim Gulis[1], Lisa Rydén[1], Julia Ellbrant[1] [1]Lunds University, Lund, Sweden, [2]Region Skåne/South Swedish Health Care Region, Malmö, Sweden	Surgery
4	**Incidence and Outcomes of Incidental Breast Lesions Detected on Non-Breast Cross-Sectional Imaging Examinations** **Jaya Anand**[1], Khai Wen Ang[1], Sarah McGarrigle[2], Dhafir Alazawi[2], Terry Boyle[2], Elizabeth Connolly[2] [1]Trinity College Dublin, Dublin, Ireland, [2]Department of Breast Care, St James's Hospital, Dublin, Ireland	Genetics/Screening/Early detection
5	**Audit of Essential Oil Pessaries (EOPs) for Urogenital Atrophy (UA)** Jacqui Stringer[1,2,3], **Anne Armstrong**[1], Daisy Hopper[1] [1]The Christie NHS Foundation Trust, Manchester, [2]Division of Cancer Sciences, University of Manchester, [3]Royal London Hospital for Integrated Medicine / University College London Hospital	Living with BC/QoL/Patient perspective/Supportive care

6	**Personalised Therapy in Triple Negative breast cancer (TNBC), evaluating predictive performance of Bayesian AI Digital Twins** **Uzma Asghar**[1], Rei Kow[2], Selvakumar Anbalagan[2], Ritika Chauhan[2], Shichina Kannambath[2], Lone Gothard[3], Samantha Nimalasena[3], Jillian Noble[3], Amber Johns[4], Emre Misirlioglu[4], Barney Plummer[5], Andrew Biankin[5], Irina Babina[4], Matthew Griffiths[4], Navita Somaiah[2,3] [1]Guys and St Thomas' NHS Foundation Trust, London, UK, [2]The Institute of Cancer Research, London, UK, [3]The Royal Marsden NHS Foundation, London, UK, [4]Concr, London, UK, [5]University of Glasgow, School of Cancer Sciences, Glasgow, UK	Early breast cancer
7	**Does Language act as a Barrier to Early Breast Cancer Diagnosis? The Berkshire Experience** **Anil Babar**[1] Madhumita Bhattacharyya, Ismini Tsagkaraki, Shelley McPhee [1]Royal Berkshire Hospital, Reading, England	Metastatic breast cancer
8	**Adherence to WCRF cancer prevention recommendations before and after chemotherapy: results of the Pre-Nutritive feasibility trial** **Ibtihal Barnawi**[1,2], Giorgia Cioccoloni[1], Baek Kim[3], Amy Burkinshaw[3], Michael Zulyniak[4], Sue Hartup[3], James L. Thorne[1] [1]University of Leeds, Leeds, UK, [2]Taibah University, Madinah, Saudi Arabia , [3]The Breast Unit at the Leeds Cancer Centre, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK, [4]The University of British Columbia, Vancouver, BC, Canada	Prevention/Lifestyle
9	**Implementation of Mainstream Genetic Testing within a High-Volume breast Unit for Pathogenic Variations Associated with Breast Cancer Using R208 and R444.1 National Test Directory Criterion** **Emma Beck**[1], Soraya Conroy[1], Emma Keane[1], Bushra Rehman[1], Eleanor Wyborn[1], Catherine Brown[1], Lamb Chen[1], Josh Chatten[1], Elijah Durston-Rand[1], Blaise Sheehan[1], Elizabeth Ferguson[1], Tracie Miles[1], Alison Hunter-Smith[1], Chrissie Laben[1], Katherine Smith[1], Diana Dalgleish[1], Rebecca Bowen, Miss Nicola Laurence[1] [1]Royal United Hospitals Bath, Bath, UK	Genetics/Screening/Early detection
10	**The association of house value with stage at diagnosis and survival in breast cancer patients - results from a population-based cohort study in Northern Ireland** Sarah Baxter[2], Charlene McShane[2], **Damien Bennett**[1], Stuart A McIntosh[3,4], Meenakshi Sharma[2], Lynne Lohfeld[2], Daniel R. S. Middleton[2], Gerard Savage[1], Deirdre Fitzpatrick[1], Ann McBrien[5], David McCallion[5], Anna Gavin[2], Chris Cardwell[2] [1]Northern Ireland Cancer Registry, Belfast, N. Ireland, [2]Centre for Public Health, Queen's University Belfast, Belfast, N. Ireland, [3]The Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, N. Ireland, [4]Breast Surgery Department, Belfast City Hospital, Belfast Health and Social Care Trust, Belfast, N. Ireland, [5]Patient Representative, Belfast, N. Ireland	Prevention/Lifestyle
11	**The risk of contralateral breast cancer after radiotherapy and hormonal therapy in the NCI-Kaiser Permanente Breast Cancer Survivors Cohort** **Amy Berrington De Gonzalez**[1], Lene Veiga[2], Gretchen Gierach[2], Susan Smith[3], Rebecca Howell[3], Matthew Mille[2], Monjoy Saha[2], Rochelle Curtis[2], Cody Ramin[4], Clara Bodelon[5], Heather Feigelson[6], Erin Bowles[7], Diana Buist[8], Sheila Weinmann[9], Jacqueline Vo[2], Choonsik Lee[2] [1]The Institute Of Cancer Research, London, UK, [2]National Cancer Institute, Bethesda, USA, [3]The University of Texas MD Anderson Cancer Center, Houston,, Houston, USA, [4]Cedars-Sinai Medical Center, Los Angeles, USA, [5]American Cancer Society, Atlanta, USA, [6]Institute for Health Research, Kaiser Permanente, , Denver, USA, [7]Kaiser Permanente Washington , Seattle, USA, [8]Data-driven Strategies for Medicine & Biotechnology, Mercer Island, USA, [9]Kaiser Permanente Center for Health Research, Portland, USA	Prevention/Lifestyle

12	**Building Confidence in SACT Supportive Care: Pilot Evaluation of the Confirm for SACT Programme** Shamanga Sooriarachchi[1] **Rufina Binoy**[1], **Sarah Malawana**[1], Maduni Wickremasinghe[1], Hiba Khan[1], Emma Cox[1], Amanuel Mulugeta[1], Jaishree Bhosle[2], Johann Malawana[1] [1]Medics.Academy, Exmouth, UK, [2]Royal Masden, London, UK	Other
13	**Audit of Axillary Node Clearance: Evaluating Sentinel Node Ratio as a Predictor of Residual Nodal Disease and Its Impact on Adjuvant Therapy Initiation** **Maryam Borumand**[1], Goudarz Mazdai[1] [1]Altnagelvin Hospital, Derry, Northern Ireland	Surgery
14	**Physical Activity and Breast Cancer Recurrence and Survival in The Breast Cancer Now Generations Study** **Martina Brayley**[1,3], Michael E Jones[1,3], Esmé O'Brien[1,3], Imogen Sawyer[1,3], Marc Gunter[2,3], Kostas Tsilidis[2,3], Montserrat Garcia-Closas[1,3], Amy Berrington de González[1,3] [1]The Institute of Cancer Research, Sutton, UK, [2]Imperial College London, London, UK, [3]Cancer Epidemiology and Prevention Research Unit (CEPRU), London, UK	Prevention/Lifestyle
15	**Enhancing GP Trainee Competence in Breast Disease Assessment: A Pilot Interdisciplinary Training Programme** **Amtul Carmichael**[1], David Hallam [1]UHDB, Burton, UK	Other
16	**Leveraging Telehealth for the Prevention of Breast Cancer: A Systematic Review** **Cheryl Chong Zhiya**[1], Ray Chong Jun Rui, Jonathan Chng Jia Hao [1]National University Health System, Singapore, Singapore	Prevention/Lifestyle
17	**Telehealth - A Promising Modality in the Management of Breast Cancer** **Cheryl Chong Zhiya**[1], Jonathan Chng Jia Hao[1], Ray Chong Junrui[1] [1]National University Health System	Living with BC/QoL/Patient perspective/Supportive care
18	**WRAP53 is differently expressed in triple negative breast cancer – results from a population-based cohort** **Moa Egelberg**[1], Tommaso De Marchi[1], Lena Tran[1], Gyula Pekar[1], Fredrika Killander[1], Emma Niméus[1] [1]Lund University, Lund, Sweden	Early breast cancer
19	**Identification of patients with a genetic predisposition to breast cancer through the Breast Molecular Tumour Board** Rupa Kumar[1], **Monica Esteban**[1], Jennet Williams[1], Rachel Dean[1], Paula Proszek[1], Clare Turnbull[2,1], Alistair Ring[1,2], Zoe Kemp[1,2] [1]Royal Marsden, London, UK, [2]Institute for Cancer Research, London, UK	Genetics/Screening/Early detection
20	**Upregulation of SFRP2 influences matrix production in carcinoma-associated fibroblasts derived from male breast cancer** **Matthew Everest**[1], Fiona Saunders[1], James Hislop[1], Valerie Speirs[1] [1]University Of Aberdeen, Aberdeen, Scotland	Preclinical research
21	**Impact of COVID19 pandemic on breast cancer patient experiences of healthcare services in Northern Ireland: findings from large-scale cross-sectional survey** **Erin Fitzsimons-west**[1], Meenakshi Sharma[1], Lynne Lohfeld[1], Ann McBrien[2], Damien Bennett[3], Anna Gavin[3], Helen Mitchell[3], Sinead Hawkins[3], Gareth Irwin[4], Siobhan O'Neill[4], Charlene McShane[1] [1]Centre for Public Health, School of Medicine, Dentistry & Biomedical Sciences, Queen's University Belfast, Belfast, UK, [2]Patient advocate, Belfast, UK, [3]Northern Ireland Cancer Registry, Centre for Public Health, School of Medicine, Dentistry & Biomedical Sciences, Belfast, UK, [4]Clinical Data Group, Belfast Health and Social Care Trust, Belfast, UK	Other

22	**Risk factors for interval compared to screen-detected breast cancers: a case-only analysis of the UK Generations Cohort** **Reuben Frost**[1,2], Martina Brayley[1], Louise Johns[1], Penny Coulson[1], Michael Jones[1,2], Amy Berrington de Gonzalez[1,2], Montserrat Garcia-Closas[1,2] [1]Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK, [2]Cancer Epidemiology & Prevention Unit, The Institute of Cancer Research & Imperial College London, London, UK	Genetics/Screening/Early detection
23	**An Integrated Research Environment for Translational Breast Cancer Research within the Breast Cancer Now Biobank** **Emanuela Gadaleta**, Maryam Abdollahyan, Qianqian Zhu, Sonal Varsani, Jorge Oscanoa, Claude Chelala [1]Barts Cancer Institute, Queen Mary University of London, London, UK	Other
24	**Implementation of a Screening Pathway for ESR1 Mutation Testing: A Single Centre Experience and Preliminary Results** **Yuting Gao**[1], **Malgorzata Wojtas**[1], Hei Wan Wendy Ng[1], Lynn Dubberley[1], Julie Elliott[1], Jenny Gradwell[1] [1]Mount Vernon Cancer Centre, Northwood, UK	Genetics/Screening/Early detection

25	**Risk Factor Associations with Distinct Tumor Features in Breast Cancer: A Pooled Analysis from 24 B-CAST Studies** Daniel Adams[1], Mustapha Abubakar[2], Amber Hurson[2], Thomas Ahearn[2], Irene Andrulis[3,4], Antonis Antoniou[5], Sabine Behrens[6], Amy Berrington de Gonzalez[1], Hermann Brenner[7], Nicola Camp[8], Georgia Chenevix-Trench[9], Fergus Couch[10], Peter Devilee[11,12], Jonine Figueroa[2], Anna González-Neira[13], Mikael Hartman[14,15,16], Maartje Hooning[17,18], Anna Jakubowska[19,20], Rudolf Kaaks[6], Arto Mannermaa[21,22,23], Penelope Ottewell[24], Muhammad Rashid[25,26], William Tapper[27], Lauren Teras[28], Celine Vachon[29], Jenny Chang-Claude[6], Douglas Easton[5], Marjanka Schmidt[30], Paul Pharoah[31], **Montserrat Garcia-Closas**[1,32] [1]Division of Genetics and Epidemiology, The Institute of Cancer Research, London, UK, [2]Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, USA, [3]Fred A Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada, [4]Department of Molecular Genetics, University of Toronto, Toronto, Canada, [5]Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK, [6]Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany, [7]Cancer Prevention Graduate School, German Cancer Research Center (DKFZ), Heidelberg, Germany, [8]Department of Internal Medicine and Huntsman Cancer Institute, University of Utah, Salt Lake City, USA, [9]Cancer Research Program, QIMR Berghofer, Brisbane, Australia, [10]Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA, [11]Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands, [12]Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands, [13]Human Genotyping Unit-CeGen, Spanish National Cancer Research Centre (CNIO), Madrid, Spain, [14]Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore City, Singapore, [15]Department of Surgery, National University Health System, Singapore City, Singapore, [16]Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore, [17]Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands, [18]Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands, [19]Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland, [20]Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Szczecin, Poland, [21]Translational Cancer Research Area, University of Eastern Finland, Kuopio, Finland, [22]Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland, [23]Biobank of Eastern Finland, Kuopio University Hospital, Kuopio, Finland, [24]Sheffield Institute for Nucleic Acids (SInFoNiA), Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK, [25]Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany, [26]Department of Basic Sciences, Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH & RC), Lahore, Pakistan, [27]Faculty of Medicine, University of Southampton, Southampton, UK, [28]Department of Population Science, American Cancer Society, Atlanta, USA, [29]Department of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, USA, [30]Division Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands, [31]Department of Computational Biomedicine, Cedars-Sinai Medical Centre, Los Angeles, USA, [32]Cancer Epidemiology and Prevention Research Unity, The Institute of Cancer Research and Imperial College London, London, UK	Prevention/Lifestyle
26	**Ethnicity and routes to diagnosis for breast cancer: a population based study in England** **Toral Gathani**[1], **Alia Ahmed**[2], Uashar Badakhshan[3] [1]University Of Oxford, [2]Brighton and Sussex Medical School, [3]University of Exeter Medical School	Early breast cancer

27	**Are there associations between ABCB1 genotypes and deviation from planned taxane treatment due to side-effects in breast cancer patients? - A population-based cohort study** **Kelin Gonçalves de Oliveira**[1], Johanna Ingard[1], Saga Weitz[1], Christopher Godina[1], Jasmine Brandt[1], Karolin Isaksson[2], Helena Jernström[1] [1]Lund University and Skane University Hospital, Lund, Sweden, [2]Lund University and Kristianstad Hospital, Lund and Kristianstad, Sweden	Genetics/Screening/Early detection
28	**Omission of sentinel node biopsy in patients with normal axilla at presentation of early breast cancer and complete radiological responses to neoadjuvant chemotherapy** Ruth Parks[1], Zoe Chia, Matthew Todd, **Lauren Hadcroft**, Melek Aydin, Emanuele Garreffa, Andy Evans [1]University Hospitals of Derby and Burton NHS Foundation Trust, [2]University of Nottingham	Surgery
29	**Assessment of response to neoadjuvant chemotherapy in patients with T1-T3, N0-N1, M0 breast cancer-A single center experience** **Fatima Hayat**[1], Shaveta Mehta [1]Clatterbridge Cancer Centre	Early breast cancer
30	**Patient and treatment factors associated with the risk of wound-related complications after breast conservation surgery: A cross-sectional study** **Leah Hepburn**[1], Petra Seibold[2], David Azria[3], Jenny Chang-Claude[2], Ananya Choudhury[4], Alison Dunning[5], Gilles Defraene[6], Dirk de Ruysscher[7], Sara Gutierrez-Enriquez[8], Tiziana Rancati[9], Barry Rosenstein[10], Elena Sperk[11], Hilary Stobart[12], R. Paul Symonds[1], Marlon Veldwijk[11], Ana Vega[13], Liv Veldeman[14], Adam Webb[1], Catherine West[15], Christopher J. Talbott[1], Dr Tim Rattay[1] [1]Leicester Medical School, Leicester, England, [2]German Cancer Research Centre (DKFZ), Heidelberg, Germany, [3]Institut Du Cancer Montpellier (ICM), Montpellier, France, [4]The Christie NHS Foundation Trust, Manchester, England, [5]University Of Cambridge , Cambridge, England, [6]university Hospitals Leuven/KU Leuven, Leuven, Belgium, [7]MAASTRO Clinic, Maastricht, Netherlands, [8]Vall d'Hebron Institute of Oncology , Barcelona , Spain, [9]Fondazione IRCCS Istituto Nazionale Dei Tumor, Milan, Italy, [10]Mount Sinai School of Medicine, New York, USA, [11]University Medical Centre Mannheim, Mannheim, Germany , [12]Independent Cancer Patients' Voice (ICPV), UK Based, UK, [13]Fundacion Publica Galega De Medicina Xenomica, Sabtiago De Compostela , Spain, [14]Universiteit Ghent, Ghent, Belgium, [15]University of Manchester, Manchester, England	Surgery
31	**Taking the PROTAC-tical approach against the progesterone receptor in ER+ breast cancer** **Flavia Hughes**[1], John Caldwell[1], Renee Flaherty[1], Brad Hocking[1], Swen Hoelder[1], Zoran Rankovic[1], Cathrin Brisken[1,2] [1]The Institute of Cancer Research, London, UK, [2]Ecole polytechniquefédéralede Lausanne (EPFL), Lausanne, Switzerland	Treatment/Novel agents
32	**Patient and Public Perceptions of Artificial Intelligence in Breast Imaging and Clinical Decision-Making: A Cross-sectional Survey Study** **Alia Hussein**[1], **Amtul Carmichael**[1,2], **Kefah Mokbel**[1], **Mariam Rizk**[1] [1]The London Breast Institute, HCA, London, UK, [2]NHS, Burton upon Trent, UK	Other
33	**Self-Directed Aftercare (SDA) following breast cancer surgery: What does the evidence say?** **Anna Isaac**[1], Olinda Santin[1], Gareth Irwin[2], Katherine Mankelow[1], Louise Cousins[2], Stuart McIntosh[1,2] [1]Queen's University Belfast, Belfast, UK, [2]Belfast City Hospital, Belfast, UK	Living with BC/QoL/Patient perspective/Supportive care
34	**Evaluation of Deep Learning Architectures for Breast Cancer Classification in Mammography Images** **Melissa Jegiraj**[1], Claude Chelala[1], Oscar Maiques Carlos[1], Vivek Kumar Singh[1], Tamara Suaris[2] [1]Queen Mary University of London, London, UK, London, UK, [2]St Bartholomew's Hospital, London, UK, London, UK	Genetics/Screening/Early detection

35	**AIB1 expression and genotypes in breast cancer – significant interactions between AIB1 genotypes and radiotherapy on prognosis** Alexandra Wiberg[1], Louise Ebbesen[1], Christopher Godina[1], Karolin Isaksson[2], **Helena Jernström**[1] [11]Lund University and Skane University Hospital, Lund Skane, Sweden, [2]Lund University and Kristianstad Hospital, Lund and Kristianstad, Sweden	Genetics/Screening/Early detection
36	**Menopausal hormone therapy and risk of breast cancer in the Generations Study cohort, UK** **Michael Jones**[1,2], Montserrat Garcia-Closas[1,2], Amy Berrington de Gonzalez[1,2] [1]The Institute of Cancer Reserach, London, UK, [2]Cancer Epidemiology and Prevention Research Unit, London, UK	Prevention/Lifestyle
37	**Digital Twins for Mechanistic Investigation of Stress and NF-κB Signalling in Triple-Negative Breast Cancer** **Isabelle Jupp**[1], Aimilia Vareli[1], Sarah Becker[2], Shubhankar Sinha[2], Fabio Simoes[1], Melanie Flint[2], Simon Mitchell[1] [1]Brighton and Sussex Medical School, Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, University of Brighton and University of Sussex, Brighton, UK, [2]University of Brighton, School of Applied Sciences, University of Brighton, Centre for Lifelong Health, Brighton, UK	Preclinical research
38	**Incomplete ovarian function suppression (OFS) in premenopausal patients with oestrogen receptor positive breast cancer receiving GnRH agonists/antagonists whilst being treated with CDK4/6 inhibitors** Ansaam El-Sherif[1,2], Elizabeth Lewis-Orr[3], Mae Eales[4], Maaedah Khan[5], Mohamed El-Sherif[6], Nia Roberts[7], **Christiana Kartsonaki**[8] [1]Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK, [2]University of Sheffiled, Sheffield, UK, [3]Royal Devon University Healthcare NHS Foundation Trust, UK, [4]Manchester University NHS Foundation Trust, Manchester, UK, [5]Bradford Teaching Hospitals NHS Trust, Bradford, UK, [6]Bodleian Health Care Libraries, University of Oxford, Oxford, UK, [7]Newcastle University, Newcastle, UK, [8]Nuffield Department of Population Health, University Of Oxford, Oxford, UK	Treatment/Novel agents
39	**Combined impact of radiation therapy and NCOA3 levels in human breast cancer – Data from a population-based Swedish cohort and in vitro experiments** Louise Ebbesen[1], **Somayeh Khazaei**[1], Alexandra Wiberg[1], Christopher Godina[1], Björn Nodin[2], Kelin Gonçalves de Oliveira[1], Karolin Isaksson[3], Helena Jernström[1] [1]Lund University Cancer Center/Kamprad, Lund University and Skåne University Hospital, Barngatan, 4, SE 222 42, Lund, Sweden, [2]Lund University Cancer Center/Kamprad, Lund University, Barngatan, 4, SE 222 42, Lund, Sweden, [3]Lund University and Skåne University Hospital, Kristianstad, Sweden, Lund, Sweden	Radiotherapy
40	**Investigating the effects of chronic low dose exposure of bisphenol A on normal mammary epithelial cells** **Katharina Kusserow**[1], Ellen Austin[1], Paul Fowler[1], Valerie Speirs[1] [1]University of Aberdeen, Aberdeen, UK	Prevention/Lifestyle
41	**Automatic Pipeline for Accurate Breast Volume Assessment** **Dmitrii Lebedev**[1,2], Tim Rattay[2], Bo Wang[3], Adam Webb[2], Hasan Asfour[2] [1]University of Leicester, Leicester Cancer Research Centre, Leicester, UK, [2]University Of Leicester, Department of Genetics and Genome Biology, Leicester, UK, [3]University Of Leicester, School of Computing and Mathematical Sciences, Leicester, UK	Living with BC/QoL/Patient perspective/Supportive care

42	**Platelet-derived growth factor-CC expression in triple-negative breast cancer is associated with increased immune cell density and response to adjuvant chemotherapy** **Sophie Lehn**[1], Paulina Bolivar[1], Elisabeth Werner Rönnerman[2,5], Anikó Kovács[2,5], Matteo Bocci[1], Gyula Pekar[1], Associate professor Johan Staaf[1], Christina Möller[1], Anna Ehinger[1,4], Ana Bosch[1,3], Åke Borg[1], Barbro K Linderholm[2,5], Kristian Pietras[1] [1]Lund University, Lund, Sweden, [2]Sahlgrenska University Hospital, Gothenburg, Sweden, [3]Skåne University Hospital, Lund, Sweden, [4]Region Skåne, Lund, Sweden, [5]Sahlgrenska Center for Cancer Research, Gothenburg, Sweden	Preclinical research
43	**Risk of incomplete ovarian function suppression (OFS) using gonadotropin-releasing hormone (GnRH) agonists and antagonists in premenopausal women with estrogen receptor (ER)-positive breast cancer** **Elizabeth Lewis-orr**[1,2], Ansaam El-Sherif[1,3], Mae Eales[1,4], Maaedah Khan[1], Nia Roberts[5], Christiana Kartsonaki[6] [1]Torbay and South Devon NHS Foundation Trust, [2]Medical Sciences Division, University of Oxford, [3]University of Sheffield, STH NHS Foundation Trust, [4]Manchester University NHS Foundation Trust, [5]Bodleian Libraries, University of Oxford, [6]Clinical Trials Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford	Treatment/Novel agents
44	**'Accepting your Body after Cancer', a group-based online intervention for women treated for breast cancer: A feasibility randomised controlled trial** **Helena Lewis-smith**[1], **Abigail Jones**[1], Paul White[1], Sarah Byford[2], **Patricia Fairbrother**[3], Shelley Potter[4], Diana Harcourt[1] [1]University of the West of England, Bristol, UK, [2]King's College London, London, UK, [3]Independent Cancer Patients' Voice, London, UK, [4]University of Bristol, Bristol, UK	Treatment/Novel agents
45	**Beyond the Invitation: Women's experiences and perceptions of NHS breast screening in disadvantaged communities in Yorkshire** **Emily Lunn**[1], Joanne Cairns[1], Una Macleod[1] [1]Hull York Medical School, Hull, UK	Genetics/Screening/Early detection
46	**Real World Evidence of Adjuvant Ribociclib. In Early Breast Cancer** **Joanna Lynch**[1], **Simran Kaur Sandhu**[1], **Fharat Raja**[1], **Natasha Quyn**[1] [1]Hca Healthcare, London, UK	Early breast cancer
47	**Supporting adherence to endocrine therapy: Health Care Professionals' views on the HT&Me intervention and potential for implementation** **Lucy McGeagh**[1], Sarah-Jane Stewart[2], Raegan Barrows[3], Jan Rose[4], Lesley Turner[4], Linda Sharp[5], Eila Watson[1] [1]Oxford Brookes University, Oxford, UK, [2]University College London, London, UK, [3]University of Warwick, Coventry, UK, [4]Independent Cancer Patients' Voice, UK, [5]Newcastle University, Newcastle, UK	Living with BC/QoL/Patient perspective/Supportive care
48	**Listening, Learning, Liaising: Dynamic Public Partnership across the FAST MRI DYAMOND Trial** **Sadie Mckeown-Keegan**[1], Marian Adeyemo[1], Janice Rose[2,3], Helen Matthews[2], Rebecca Geach[1], Abi Loose[1], Sam Harding[1], Lyn Jones[1] [1]North Bristol NHS Trust, Bristol, UK, [2]Patient Co-applicant, UK, [3]Independent Cancer Patients' Voice, London, UK	Genetics/Screening/Early detection
49	**Pneumonitis in breast cancer patients treated with adjuvant Abemaciclib- a single centre experience** **Shaveta Mehta**[1], Chloe Johns[2], Dawn Ledsom[1], Helen Wong[1], Clare Hart[1] [1]The Clatterbridge Cancer Centre NHS Foundation trust, Liverpool, UK, [2]University of Liverpool, Liverpool	Treatment/Novel agents
50	**Counting the Seconds: Frequency and Timing of metastatic breast cancer recurrences after primary breast cancer** **Helen Mitchell**[1], Sinead Hawkins[1], Amisha Ashok[1], Jackie Kelly[1], Gerard Savage[1], Deirdre Fitzpatrick[1], Gareth Irwin[3], Ann McBrien[2], Gemma Potter[3], Conor O'Neill[4], Thérèse McCartney[3], Damien Bennett[1] [1]Northern Ireland Cancer Registry, Belfast, UK, [2]Patient Advocate, Belfast, UK, [3]Belfast Health and Social Care Trust, Belfast, UK, [4]Western Health and Social Care Trust, Derry- Londonderry, UK	Metastatic breast cancer

51	**Retrospective Comparative Analysis of Surgical and Patient-Reported Outcomes Following Immediate Pre-Pectoral Implant-Based Breast Reconstruction with Polyurethane Implants Alone vs Micro-textured Implants with Acellular Dermal Matrix** **Aman Kaur More**[1], Muskaan Khosla[1], Senthurun Mylvaganam[1] [1]Royal Wolverhampton Trust, Wolverhampton, UK	Surgery
52	**Integrative multiomic analysis identifies molecular markers of metastatic spread in ER-positive/HER2-negative breast cancer** **Sergio Mosquim Junior**[1], Måns Zamore[1], Johan Vallon-Christersson[1], Lisa Ryden[1,2], Fredrik Levander[1,3] [1]Lund University, Lund, Sweden, [2]Skåne University Hospital, Lund, Sweden, [3]National Bioinformatics Infrastructure Sweden (NBIS), Lund, Sweden	Genetics/Screening/Early detection
53	**A systematic review of validated and adapted prediction models for risk of breast cancer** **Dr Hannah Nentwich**[1], Dr Christiana Kartsonaki[2], Dr Ansaam Al-Sherif[1], Dr Beatrice Forder[1], Dr Georgina Miles[1], Zhequing Zhang[1], Rebecca Nolan[1], Alice Honigmann[1], Aparna Sridhar[1], Hasan Al-Sattar[1], Frederica Re[1], Thomas Morgan[1], Mae Eales[1], Aoife Lyford[1], Sofia Baldelli[1], Imogen Wilkinson[1], Kyriaki Michailidou[3], Hassan Kamar[1], Natnicha Manaboriboon[1] [1]Medical Sciences Division, University of Oxford, Oxford,[2]Nuffield Department of Population Health, University of Oxford, Oxford, [3]Cyprus Institute of Neurology and Genetics, Ayios Dhometios, Cyprus	Genetics/Screening/Early detection
54	**Preventing breast cancer after chest radiotherapy: Developing a national interventional cohort study** **Esmé O'Brien**[1], Sacha Howell[2], Sharon Dixon[3], Amy Berrington de González[1], Aislinn Macklin-Doherty[1,4] [1]The Institute of Cancer Research, London, UK, [2]The Christie NHS Foundation Trust, Manchester, UK, [3]The University of Oxford, Oxford, UK, [4]The Royal Marsden NHS Foundation Trust, London, UK	Prevention/Lifestyle
55	**The OxMINT project- improving quality of life and function for breast cancer patients with metastatic bone disease** **Jennifer Paskins**[1], Yaron Berkowitz, James Teh, Nicolas Beresford-Cleary, Euan Stirling, Muhammad Riaz, Ather Siddiqi, Emma Kenney-Herbert, Hayley Jones, Clare Jacobs, Victoria Bradley [1]Oxford University Hospitals	Living with BC/QoL/Patient perspective/Supportive care
56	**Trastuzumab deruxtecan for HER2-Positive Metastatic Breast Cancer: The Leeds Experience** **Ammarrah Patel**[1], Chris Twelves[1,2] [1]Leeds Teaching Hospitals NHS Trust, Leeds, UK, [2]University of Leeds, Leeds, UK	Metastatic breast cancer
57	**PRE-ACT-01: The Prediction of Radiotherapy side Effects using explainable AI for patient Communication and Treatment modification-01 Trial** **Tim Rattay**[1], Karolien Verhoeven[2], Marie Bergeaud[3], Guido Bologna[4], Gabriella Cortellessa[5], Andre Dekker[6], Francesca Fracasso[5], Manuela Joore[6], Iordanis Koutsopoulos[7], Yuqin Liang[2], Andre Panisson[8], Alan Perotti[8], Bram Ramaekers[2,6], Cheryl Roumen[9], Johan van Soest[2,10], Hilary Stobart[11], Christopher Talbot[1], Adam Webb[1], Sofia Rivera[3,12], PRE-ACT Study Consortium [1]University of Leicester, Leicester, UK, [2]Maastricht University Medical Centre+, Maastricht, Netherlands, [3]UNICANCER, Paris, France, [4]HES-SO University of Applied Sciences and Arts of Western Switzerland, Geneva, Switzerland, [5]Consiglio Nazionale delle Ricerche (CNR), Rome, Italy, [6]Maastricht University, Maastricht, Netherlands, [7]Athens University of Economics and Business, Athens, Greece, [8]CENTAI Institute, Turin, Italy, [9]Breast Cancer Foundation Netherlands (BVN), Utrecht, Netherlands, [10]Medical Data Works, Maastricht, Netherlands, [11]Independent Cancer Patients' Voice, London, UK, [12]Institut Gustave Roussy, Paris, France	Trials in progress

58	**Prediction of sentinel lymph node status in early breast cancer using breast imaging as an alternative to surgical staging – A systematic review and meta-analysis** **Cornelia Rejmer**[1], Malin Hjärtström[1], Pär-Ola Bendahl[1], Looket Dihge[1], Ida Skarping[1], Daqu Zhang[2], Magnus Dustler[3], Professor Lisa Rydén[1] [1]Department of Clinical Sciences, Lund University, Lund, Sweden, [2]Centre for Environmental and Climate Science, Lund University, Lund, Sweden, [3]Department of Translational Medicine, Lund University, Malmö, Sweden	Early breast cancer
59	**Air Pollution and Breast Cancer Risk in the Generations Study, UK** **Zoey Richards**[1,2], Amy Berrington de Gonzalez[1,2], Michael E. Jones[1,2], Marc Chadeau[3], Roel Vermeulen[4], Daniela Fecht[3], Montserrat Garcia-Closas[1,2] [1]Institute Of Cancer Research, London, UK, [2]Cancer Epidemiology and Prevention Research Unit; The Institute of Cancer Research and Imperial College London, London, UK, [3]Imperial College London, London, UK, [4]Utrecht University, Utrecht, NL	Prevention/Lifestyle
60	**Longitudinal body mass index patterns and associations with tumour characteristics in breast cancer patients** Sara Tamas[1], **Ann Rosendahl**[1] [1]Lund University, Clinical Sciences Lund, Oncology, Lund, Sweden	Prevention/Lifestyle
61	**The Influence of PET Scanning in the Management of Patients with Breast Cancer** **Dea Saldanha**[1], **Catherine Pembroke**[2] [1]Cardiff University, Cardiff, UK, [2]Velindre Cancer Centre, Cardiff, UK	Radiology
62	**A survey of the acceptability of wearing the SENSTM motion exercise tracking device in patients being treated for early and advanced breast cancer** **Emily Sharp**[1], Dorcas Adjei[1], Sarah Egan[1], Claire Ryan[1], Catherine Harper-Wynne[1] [1]Maidstone And Tunbridge Wells NHS Trust, Maidstone, UK	Prevention/Lifestyle
63	**Diagnosis to Survival: a systematic scoping review of the experiences of Black women with breast cancer in the UK** **Nimreth Kaur Sidhu**[1], Robert Horne[1], Nevo Burrell, Olufikayo Bamidele[2], Verna Lavender[4], Arnie Purushotham[3], Dr Erica Warner[5], Zoe Moon[1] [1]University College London, London, UK, [2]Hull York Medical School, University of Hull, Hull, UK, [3]King's College London, London, UK, [4]Guy's and St Thomas NHS Foundation Trust, London, UK, [5]Harvard Medical School, Boston, United States of America	Other
64	**Biographical Continuity: A Qualitative Study of the Role of Complementary and Alternative Medicine usage after Breast Cancer Diagnosis** **Richard Simcock**[1], Joana Almeida[2], Kavi Sharma[3], Jonathan Gabe[4], John Anderson[3] [1]University Hospitals Sussex NHS Foundation Trust, Brighton, UK, [2]Faculty of Health, Community & Life Sciences, University of Bedfordshire, Luton, UK, [3]Brighton and Sussex Medical Schools, Brighton, UK, [4]School of Law and Social Sciences, Royal Holloway, University of London, London, UK	Living with BC/QoL/Patient perspective/Supportive care
65	**Evaluating Attendance Rates for NHS Breast Screening: A Primary Care Audit in the North East of England** **Rose Stacey**[1] [1]Newcastle Upon Tyne Hospitals , [2]University of Newcastle Evaluating Attendance Rates for NHS Breast Screening: A Primary Care Audit in the North East of England	Genetics/Screening/Early detection
66	**Empowering and educating secondary breast cancer patients through the UK's first Secondary Breast Cancer Patient Summit** **Lesley Stephen**[1], Carlo Palmieri [1]Make 2nds Count, Edinburgh, UK	Living with BC/QoL/Patient perspective/Supportive care

67	**Giving metastatic patients hope through a unique trial matching service** **Lesley Stephen**[1] [1]Make 2nds Count, Edinburgh, UK	Metastatic breast cancer
68	**Expanding the spectrum of rare breast cancers – HER2 positive Invasive Lobular Carcinoma with Extracellular Mucin:Histological comparison with other mucin-producing breast cancers to aid diagnosis** **Souganthy Sundaramoorthy**[1], Sunayana Misra[2,3], Andrew Clayton Lee[4], Jenny Banks[5], Aralola Olusanya[6], Adetope Adegbayibi[6], Dermot Ryan[7], Puay Hoon Tan[2,8], Abeer Shaaban[9,10] [1]University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, [2]Luma Medical Centre, Singapore, [3]Sir Gangaram Hospital, New Delhi, India, [4]Gleneagles Medical Centre, Singapore, [5]North Devon District Hospital, Barnstaple, UK, [6]North Devon District Hospital, Barnstaple, UK, [7]Queen Elizabeth Hospital, Birmingham, UK, [8]Parkway Laboratories, Singapore, [9]Queen Elizabeth Hospital Birmingham, UK, [10]University of Birmingham, UK	Pathology
69	**A National Survey of Cavity Shave Practice in Breast Conserving Surgery Amongst UK Breast Surgeons** Buket Ertansel[1], Alicia Skervin, Anup Sharma, **Sarah Tang**[1] [1]St George's Hospital	Surgery
70	**Evaluation of Clinic Recalls for Early Breast Cancer patients on a Personalised Stratified Follow up programme** **May Teoh**[1,2], Emily Tripp[1], Manish Kothari[1] [1]Ashford and St Peter's Hospital, [2]Royal Surrey Hospital	Other
71	**Mainstreaming Genomics in a Breast Cancer Unit, How accurate are the nurse pre-conceptions of Nurse Led Genomic Mainstreaming in practice?** **Sara Trotman**	Genetics/Screening/Early detection
72	**Rethinking the message on alcohol and breast cancer: findings from a Delphi Study** Lindsey Coombes[1], Cathy Liddiard[1], Jennifer Seddon[1], Fiona Matley[1], **Eila Watson**[1], Emma Davies[1] [1]Oxford Brookes University, Oxford, UK	Prevention/Lifestyle
73	**Progress with the SWEET Trial – Supporting women with breast cancer with adherence to adjuvant endocrine therapy** **Eila Watson**[1], Lucy McGeagh[1], Raegan Barrows[6], Sarah-Jane Stewart[3], Janet Dunn[6], Mary Wells[8], Guy Taylor[2], Jan Rose[7], Lesley Smith[7], Peter Donnelly[5], Henry Cain[4], Linda Sharp[2] [1]Oxford Brookes University, Oxford, UK, [2]Newcastle University, Newcastle, UK, [3]University College London, London, UK, [4]Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, [5]Torbay and South Devon NHS Foundation Trust, Torquay, UK, [6]Warwick Clinical Trials Unit, Warwick University, Coventry, UK, [7]Independent Cancer Patients Voices, London, UK, [8]Imperial College London, London, UK	Trials in progress
74	**Patients with breast cancer have elevated plasminogen activator-1 and delayed fibrinolysis** Louise MacDonald[1], Rachel Moir[2], Angela Strachan[2], Mattia Piana[3], Joanna Smith[2], Charlotte James[2], Jayne Innes[3], Sarah Murdoch[3], Joan Wilson[3], Shirley Richardson[2], Nicola Mutch[1], Valerie Speirs[1], Beatrix Elsberger[2], **Claire Whyte**[1] [1]University of Aberdeen, Aberdeen, UK, [2]Aberdeen Royal Infirmary, Aberdeen, UK, [3]NHS Grampian Biorepository, Aberdeen, UK	Other
75	**Development and evaluation of a one-day communication workshop for healthcare professionals working in a metastatic breast cancer (MBC) setting** **Niomie Wogan**[1], **Valerie Jenkins**[1], Ivonne Solis-Trapala[2], Ruth Habibi[1], Lesley Fallowfield[1] [1]SHORE-C Brighton & Sussex Medical School, University of Brighton & University of Sussex, Brighton, England, [2]Keele University, Keele, England	Metastatic breast cancer

| 76 | **The Power of Less: Evidence-Based De-escalation of Denosumab for Optimal Patient Outcomes and Resource Utilisation**
Hei Wan Wendy Ng[1], **Malgorzata Wojtas**[1], **Yuting Gao**[1]
[1]Mount Vernon Cancer Centre, Northwood, UK | Other |

The UK Interdisciplinary Breast Cancer Symposium is supported by: